Eye injections a thing of past soon?

Image
IANS London
Last Updated : Mar 06 2014 | 1:06 PM IST

In what could be a breakthrough for the millions worldwide suffering from age-related eye disorders, scientists have found that drugs could be successfully administered by eye drops rather than unpleasant and expensive eye injections.

The current treatment of injecting drugs into the eye is uncomfortable, detested by patients and often needs repeated monthly injections in hospital for as long as 24 consecutive months.

The new research demonstrates that it is possible to create formulations of tiny nanoparticles loaded with the age-related macular degeneration (AMD) drug Avastin and deliver significant concentrations to the back of the eye.

"The development of eye drops that can be safely and effectively used in patients would be a magic bullet - a huge breakthrough in the treatment of AMD and other debilitating eye disorders," said professor Francesca Cordeiro from the Institute of Ophthalmology at the University College London.

One in five people over 75 have age-related macular degeneration worldwide.

Effective delivery of drugs to the retina of the eye is considered one of the most challenging areas in drug development in ophthalmology owing to the presence of anatomical barriers.

The researchers showed in animal models a formulation system to get substances including Avastin across the barriers in the eye and transport them across the cells of the cornea.

"All the components we used are safe and well established in the field, meaning we could potentially move quite quickly to get the technology into trials in patients," added Ben Davis from the university's institute of ophthalmology.

The research was published in nanotechnology journal Small.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 06 2014 | 1:00 PM IST

Next Story